SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-12-12
Accession Number: 0001493152-25-027406
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225027406/filename1.htm

Chunk 61 of 89
Word Count: 1471
Character Count: 9440

Document Content:

common stock are fully paid and non-assessable. Preferred Stock Our Amended and Restated COI gives the board of directors the power to issue shares of preferred stock in one or more series without stockholder approval. The board of directors has the discretion to determine the designations, rights, qualifications, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing the board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock. Stock Options

of the date of this prospectus, we had reserved the following shares of common stock for issuance pursuant to stock options under the
2024 Equity Incentive Plan:

shares of our common stock reserved for issuance under stock option agreements issued pursuant
to the 2024 Equity Incentive Plan with a weighted average exercise price of $1.00 per share;
and

shares of our common stock reserved for future issuance under the 2024 Equity Incentive Plan
(which is equal to % of our issued and outstanding common stock immediately after the consummation
of this offering, less the number of outstanding option grants).

Transfer
Agent and Registrar

The
transfer agent and registrar of our common stock is Issuer Direct Corporation.

Representative’s
Warrant

have agreed to issue the Representative’s Warrant to the representative of the underwriters of this offering as a portion of the
underwriting compensation payable in connection with this offering. The Representative’s Warrant shall be exercisable for
shares of our common stock (or 5% of the shares of common stock sold in this offering, including any shares of common stock sold pursuant
to the exercise of the underwriters’ over-allotment option). The Representative’s Warrant shall contain customary “cashless
exercise” provisions and shall be exercisable at any time, and from time to time, in whole or in part, from the first day of the
seventh month after the closing of this offering to the date that is five years from the date of commencement of sales in this offering
at an exercise price equal to the initial public offering price of the shares of common stock. Please see “Underwriting
— Representative’s Warrant” for further information.

Lock-Up
Agreements

Pursuant
to certain “lock-up” agreements, our executive officers, directors and our existing stockholders have agreed, subject to
certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention
to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic
risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or exchangeable
or exercisable for any common stock, whether currently owned or subsequently acquired, without the prior written consent of the representative
of the underwriters, for a period of six (6) months following the closing of this offering.

addition, we have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise
dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that
transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any common
stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired,
without the prior written consent of the representative of the underwriters, for a period of six (6) months following the closing of
this offering.

Delaware
Law and Certain Charter and Bylaw Provisions

Our
Charter and Bylaws and the DGCL contain provisions, which are summarized in the following paragraphs, that are intended to enhance the
likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover
battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of our board of directors to maximize
stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect
and may delay, deter or prevent a merger or acquisition of the Company by means of a tender offer, a proxy contest or other takeover
attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing
market price for the shares of Common Stock held by stockholders.

Authorized
but Unissued Capital Stock

Delaware
law does not require stockholder approval for any issuance of shares that are authorized and available for issuance. However, the listing
requirements of the NYSE, which would apply so long as our Common Stock remains listed on the NYSE, require stockholder approval of certain
issuances equal to or exceeding 20% of the then outstanding voting power of our capital stock or then outstanding number of shares of
Common Stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional
capital or to facilitate acquisitions.

Our
board of directors may generally issue shares of one or more series of preferred stock on terms calculated to discourage, delay or prevent
a change of control of the Company or the removal of our management. Moreover, our authorized but unissued shares of preferred stock
will be available for future issuances in one or more series without stockholder approval and could be utilized for a variety of corporate
purposes, including future offerings to raise additional capital, to facilitate acquisitions and employee benefit plans.

One
of the effects of the existence of authorized and unissued and unreserved Common Stock or preferred stock may be to enable our board
of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt
to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of
our management and possibly deprive our stockholders of opportunities to sell their shares of Common Stock at prices higher than prevailing
market prices.

Delaware
Law

will not be subject to the provisions of Section 203 of the DGCL, regulating corporate takeovers. In general, those provisions prohibit
a Delaware corporation, including those whose securities are listed for trading on the Nasdaq, from engaging in any business combination
with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder,
unless:

●	the
transaction is approved by the board of directors before the date the interested stockholder
attained that status;

●	upon
consummation of the transaction that resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding
at the time the transaction commenced; or

or after such time the business combination is approved by the board of directors and authorized
at a meeting of stockholders by at least two-thirds of the outstanding voting stock that
is not owned by the interested stockholder.

Removal
of Directors; Vacancies and Newly Created Directorships

Under
the DGCL, directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election
of directors. In addition, under the DGCL, subject to the rights granted to one or more series of preferred stock then outstanding, any
vacancies on our board of directors, and any newly created directorships, will be filled only by the affirmative vote of a majority of
the directors then in office, even if less than a quorum, by a sole remaining director or by the stockholders.

Cumulative Voting

Under
Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. Our Charter does not authorize cumulative voting. Therefore, stockholders holding a majority in voting power of the shares of
our stock entitled to vote generally in the election of directors will be able to elect all our directors.

Special
Stockholder Meetings

Our
Bylaws provide that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors.
Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions
may have the effect of deterring, delaying or discouraging hostile takeovers, or changes in control or management of the Company.

Director
Nominations and Stockholder Proposals